DISCOVERIES REPORTS (ISSN 2393249X), 2021, volume 4

Access FULL text of the manuscript here:

GO BACK to 2021, VOLUME 4

CITATION: Sekaran S, Jagani RP, Waleed MS, Celi CSV, Marzban S. Latent tuberculosis and COVID-19 disease. Discoveries Reports 2021; 4(3): e26. DOI: 10.15190/drep.2021.11 Submitted: Aug. 13, 2021; Revised: Dec. 23, 2021; Accepted: Dec. 23, 2021; Published: Dec. 31, 2021

Latent tuberculosis and COVID-19 disease

Sruthi Sekaran (1,*), Ravi Pankajbhai Jagani (1), Madeeha Subhan Waleed (1), Claudia Samanta Villa Celi (1), Sima Marzban (2)

(1) Larkin Community Hospital, Miami, FL, USA
(2) Division of Clinical and Translational Research, Larkin Health System, Miami, Florida, USA 

* Corresponding author: Dr. Sruthi Sekaran, Division of Clinical and Translational Research, Larkin Health System, 7031 SW 62nd Ave, South Miami, FL 33143, USA; ORCID #: 0000-0002-5673-6864; Phone: +91-9663981190; Email: sruthisekaran@gmail.com

Abstract

Since the start of the COVID-19 pandemic in 2020, there has been chaos in the world. With the COVID-19 cases rising, many other medical diseases have been ignored and not prioritized. One of these crucial diseases is Tuberculosis (TB). TB is a highly infectious bacterial respiratory disease. Every year there are millions of cases that are registered all around the world. TB is seen in two forms, an active and a latent form. In both of the states, the individual with TB is immunocompromised. This is of great importance, as COVID-19 is known to readily infect individuals in an immunocompromised state more than those with a healthy immune system. Although a little investigation about coexisting infections with COVID-19 and TB is conducted, it is important to consider many factors that can be beneficial to help treat these patients with both conditions effectively and promptly. A few of these factors are pathophysiological relation, diagnostic measurements, effects of each condition on the other, and approaches to treatment. Through a literature review of available information, we summarized the knowledge regarding the correlation between Latent TB infection and COVID-19 infection. The main objective of this publication is to provide a brief overview of how the two conditions overlap with one another. The article also provides a clinical review of how to approach these two conditions in a scenario where an individual is found to be infected with both Latent TB and COVID-19.

References

1.  Waleed MS, Sadiq W, Azmat M. Understanding the Mosaic of COVID-19: A Review of the Ongoing Crisis. Cureus. 2020;12(3): e7366.
2. Houben R.M.G.J., Dodd P.J. The global burden of latent tuberculosis infection: a Re-estimation using mathematical modeling. PLoS Med. Oct. 2016;13(10)
3. Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A re-estimation Using Mathematical Modelling. PLoS Med. 2016;13(10):e1002152.
4. World Health Organization. Global tuberculosis report 2020; https://www.who.int/publications-detail-redirect /9789240013131
5. Chen, Y., et al., Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. medRxiv, 2020.
6. Liu, C., et al., Severe COVID-19 cases with a history of active or latent tuberculosis. Int J Tuberc Lung Dis, 2020. 24(7): p. 747-749.
7. Akbar, H., et al., Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Mimicking as Pulmonary Tuberculosis in an Inmate. Cureus, 2020. 12(6): p. e8464.
8. Tham, S.M., et al., Four Patients with COVID-19 and Tuberculosis, Singapore, April-May 2020. Emerg Infect Dis, 2020. 26(11): p. 2764-2766.
9. Torre, A., et al., Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy. Respir Med, 2020. 175: p. 106204.
10. Visca D, Ongc, C, Tiberi S, et al.: Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology. 2020. 151-165.
11. Houben R and Dodd P. The Global Burden of Latent Tuberculosis Infection: A re-estimation Using Mathematical Modelling. PLoS Med. 2016 Oct; 13(10).
12. CDC: Latent TB Infection and TB Disease. 2020. Accessed July 23, 2021
13. Mokhtari T, Hassani F, Ghaffari N et al. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. J Mol Histol. 2020 Oct 4: 1–16.
14. Ai J, Ruan Q, Liu Q, et al. Updates on the risk factors for latent tuberculosis reactivation and their management. Emerging Microbes and Infections. 2016. 5 (1).
15. CDC: Symptoms of COVID-19. 2021. Accessed July 23, 2021
16. Burki T. The global cost of tuberculosis. Respiratory medicine. 2018. 6 (1).
17. Echeverría G, Espinoza W, de Waard JH. How TB and COVID-19 compare: An opportunity to integrate both control Programmes. Latest TOC RSS. International Union Against Tuberculosis and Lung Disease; 2020.
18. Kant S, and Tyagi R.: The impact of COVID-19 on tuberculosis: challenges and opportunities. Ther Adv Infectious Dis. 2021. Vol.8: 1–7.
19. Crisan-Dabija R, Grigorescu C, Pavel C, et al.: Tuberculosis and COVID-19: Lessons from the Past Viral OuTBreaks and Possible Future Outcomes. Canadian Respiratory Journal. 2020.
20. Khalil B, Elemam N, and Maghazachi A.: Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021; 19: 976–988.
21. Guan W, Ni Z, Hu Y, et al.: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Feb 28.
22. Diao B, Wang C, Tan Y, et al.: Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). Front. Immunol., 2020; 11: 827.
23. Etna M, Giacomini E, Severa M, et al: Pro- and anti-inflammatory cytokines in tuberculosis: A two-edged sword in TB pathogenesis. Seminars in Immunology. 2014. 26 (6) 543-551.
24. Romero-Adrian TB, Leal-Montiel J, Fernández G, Valecillo A. Role of cytokines and other factors involved in the Mycobacterium tuberculosis infection. World J Immunol 2015; 5(1): 16-50
25. Wu J, Wang S, Lu C, et al.: Multiple cytokine responses in discriminating between active tuberculosis and latent tuberculosis infection. Tuberculosis (Edinb). 2017 Jan; 102:68-75.
26. Merad M and Martin J.: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nature Reviews Immunology. 2020. 20: 355-362.
27. Sheerin D, Abhimanyu, Wang X, et al.: Systematic evaluation of transcriptomic disease risk and diagnostic biomarker overlap between COVID-19 and tuberculosis: a patient-level meta-analysis. MedRxiv. Preprint. 2020 Nov 26.
28. WHO: Impact of the COVID-19 pandemic on TB detection and mortality in 2020. 2021 Accessed August 4, 2021.
29. McQuaid CF, Vassall A, Cohen T, Fiekert K, White RG. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis. 2021;25(6):436-446.
30. Alene KA, Wangdi K, Clements ACA. Impact of the COVID-19 Pandemic on Tuberculosis Control: An Overview. Trop Med Infect Dis. 2020. Jul 24;5(3):123.
31. Zellweger JP, Sotgiu G, Corradi M, Durando P. The diagnosis of Latent tuberculosis Infection (LTBI): Currently Available TESTS, future developments, and perspectives to eliminate tuberculosis (TB). La Medicina del lavoro. Mattioli 1885 srl; 2020.
32. Yamasue M, Komiya K, Usagawa Y, Umeki K, Nureki S-I, Ando M, et al. Factors associated with false-negative interferon-γ release assay results in patients with tuberculosis: A systematic review with meta-analysis. Scientific reports. Nature Publishing Group UK; 2020.
33. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with Severe Coronavirus Disease 2019 (COVID-19): The perspectives of CLINICAL Immunologists from China. Clinical Immunology. Academic Press; 2020.
34. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F et al. COVID-19 diagnosis and management: A comprehensive review-Journal of internal medicine. John Wiley and Sons Inc.; 2020.
35. Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. International Journal of Infectious Diseases. Elsevier Inc.; 2014.
36. Moorlag SJCFM, Arts RJW, Crevel Rvan, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clinical microbiology and infection. Elsevier Ltd; 2019.
37. Gupta PK. New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19? Cellular immunology. Elsevier Inc.; 2020.
38. Moulson AJ, Av-Gay Y. BCG immunomodulation: From the 'hygiene hypothesis' To COVID-19. Immunobiology. Elsevier GmbH.; 2021.
39. Different COVID-19 vaccines. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2021.
40. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected World Health Organization. World Health Organization; 2020.
41. Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P. COVID-19 treatment options: A difficult journey between failed attempts and experimental drugs. Internal and emergency medicine. Springer International Publishing; 2021.
42 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: Consider cytokine Storm syndromes and immunosuppression. Lancet (London, England). Elsevier Ltd.; 2020.
43. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19. The New England journal of medicine. Massachusetts Medical Society; 2021.
44. Gopalaswamy R, Subbian S. Corticosteroids for COVID-19 therapy: Potential implications on tuberculosis. International journal of molecular sciences. MDPI; 2021.
45. Patil S, Jadhav A. Short course of high-dose steroids for anaphylaxis caused a flare-up of tuberculosis: A case report. Journal of translational internal medicine. Sciendo; 2019.
46. Ai J-W, Ruan Q-L, Liu Q-H, Zhang W-H. Updates on the risk factors for latent tuberculosis reactivation and their management. Emerging microbes and infections. Nature Publishing Group; 2016.
47. Centers for Disease Control and Prevention. Treatment regimens for latent TB infection (LTBI). Atlanta, GA: Centers for Disease Control and Prevention. 2016.
48. Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh Jr CR, Crane CM, Burgos M, LoBue P. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020.
49. Schluger NW, Burzynski J. Recent advances in testing for latent TB. Chest. 2010 Dec 1;138(6):1456-63.
50. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state. Chest. 2012 Jul 1;142(1):63-75.
51. Dobler CC, Martin A, Marks GB. The benefit of treatment of latent tuberculosis infection in individual patients. European Respiratory Journal. 2015 Nov 1;46(5):1397-406.
52. Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respiratory research. 2010 Dec;11(1):1-7.
53. Borisov AS, Morris SB, Njie GJ, Winston CA, Burton D, Goldberg S, Woodruff RY, Allen L, LoBue P, Vernon A. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. Morbidity and Mortality Weekly Report. 2018 Jun 29;67(25):723.
54. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology. 2010 May;15(4):603-22.
55. Cardano PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis. 2006 May 1;86(3-4):273-89.[59] GUIDANCE E. Management of contacts of MDR TB and XDR TB patients.
56. International Union against Tuberculosis Committee on Prophylaxis Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982; 60(4):555–564
57. Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014; 161(6):419–428.
58. Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017; 167(4):248–255.
59. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of Rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365(23):2155–2166.
60. Centers for Disease Control and Prevention Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep. 1998; 47(RR-20):1–58.
61. Gwee A, Coghlan B, and Curtis N. Question 1: what are the options for treating latent TB infection in children? Arch Dis Child. 2013; 98(6):468–474.
62. Sandgren A, van der Werf M. ECDC guidance on the management of contacts of MDR-TB and XDR-TB patients. Eur Respir J. 2012; 40(Suppl 56):206.
63. van der Werf MJ, Langendam MW, Sandgren A, Manissero D. Lack of evidence to support policy development for the management of contacts of multidrug-resistant tuberculosis patients: two systematic reviews. Int J Tuberc Lung Dis. 2012; 16(3):288–296.
64. Holland DP, Sanders GD, Hamilton CD, Stout JE. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One. 2012; 7(1): e30194.
65. Lin L., Lu L., Cao W., Li T. “Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg. Microb. Infect. Jan. 2020; 9(1):727–732.
66. Khayat M, Fan H, and Vali Y.: COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report. Department of Pulmonology. 2021.
67. WHO Coronavirus Disease (COVID-19) Dashboard (Accessed on 9 March 2021).
68. Stochino C., Villa S., Zucchi P., Parravicini P., Gori A., Raviglione M.C. Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital. Eur. Respir. J. 2020; 56.
69. Vozoris N.T., Seemangal J., Batt J. Prevalence, screening and treatment of latent tuberculosis among oral corticosteroid recipients. Eur. Respir. J. 2014; 44:1373–1375.
70. Garg N., Lee Y.M. Reactivation TB with Severe COVID-19. Chest. 2020; 158:A777.
71. Hospital M.G. Tuberculosis Reactivation Risk Mitigation for Steroids. [(Accessed on 20 January 2021)];
72. Soliman R, Brassey J, Pluddemann A, Henegahn C. Does BCG vaccination protect against acute respiratory infections and COVID-19? A rapid review of current evidence. University of Oxford. 2020 April 23.
73. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced mortality for COVID-19. MedRxiv. 2020 Jan 1.
74. Yamamoto N., Bauer G. Apparent difference in fatalities between Central Europe and East Asia due to SARS-COV-2 and COVID-19: Four hypotheses for a possible explanation. Med Hypotheses. 2020.
75. Takahashi H. Role of latent tuberculosis infections in reduced COVID-19 mortality: Evidence from an instrumental variable method analysis. Medical hypotheses. 2020 Nov 1;144:110214.
76. Rapaka RR, Hammershaimb EA, Neuzil KM. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2021 Mar 6.
77. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur. Rev. Med. Pharmacol. Sci. 2021 Feb 1;25(3):1663-9.
78. Chen W. Promise and challenges in the development of COVID-19 vaccines. Human Vaccines and Immunotherapeutics. 2020 Nov 1;16(11):2604-8.
79. COVID C, Team R. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—the United States, December 14–23, 2020. Morbidity and Mortality Weekly Report. 2021 Jan 15;70(2):46.
80. COVID C. Response TeamFood and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—the United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51.
81. Kadali RA, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. International Journal of Infectious Diseases. 2021 May 1;106:376-81.
82. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MC. Incidence of Venous Thromboembolism in Hospitalized Patients with COVID-19. Journal of Vascular Surgery. Venous and Lymphatic Disorders. 2021 Mar;9(2):536.
83. Thomas SJ, Moreira Jr ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. New England Journal of Medicine. 2021 Nov 4;385(19):1761-73.
84. Tamuzi JL, Ayele BT, Shumba CS, Adetokunboh OO, Uwimana-Nicol J, Haile ZT, Inugu J, Nyasulu PS. Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. BMC infectious diseases. 2020 Dec;20(1):1-8.
85. Tuberculosis and COVID-19. World Health Organization. World Health Organization; 2020.
86.    Uwishema O, Adanur I, Babatunde AO, Hasan MM, Elmahi OK, Olajumoke KB, Aborode AT, Emmanuella N, Costa AC, Ahmad S, Essar MY. Viral infections amidst COVID‐19 in Africa: implications and recommendations. Journal of Medical Virology. 2021 Dec;93(12):6798-802.